Dermavant Sciences, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$22.8M
Doctors Paid
13,703
Transactions
151,076
2024 Total
$6.8M
Payment Breakdown by Category
Research$8.9M (39.2%)
Consulting$3.6M (15.6%)
Food & Beverage$3.0M (13.0%)
Travel$832,583 (3.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.9M | 15,234 | 39.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6.3M | 2,486 | 27.8% |
| Consulting Fee | $3.6M | 827 | 15.6% |
| Food and Beverage | $3.0M | 129,480 | 13.0% |
| Travel and Lodging | $832,583 | 2,369 | 3.7% |
| Grant | $151,050 | 1 | 0.7% |
| Education | $12,962 | 679 | 0.1% |
Payments by Type
General
$13.8M
135,842 transactions
Research
$8.9M
15,234 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TAPINAROF CREAM 1% IN SUBJECTS WITH ATOPIC DERMATITIS | $4.9M | 0 | 5,240 |
| A PHASE 3 EFFICACY AND SAFETY STUDY OF TAPINAROF FOR THE TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN CHILDREN WITH ADULTS | $2.7M | 0 | 8,427 |
| A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of plaque psoriasis in intertriginous areas | $536,093 | 0 | 771 |
| A Phase 4, open-label study to investigate the efficacy and safety of VTAMA(tapinarof) cream, 1% in the treatment of plaque psoriasis occurring in the head and neck region | $332,244 | 0 | 285 |
| DMVT-505-3004 | $174,880 | 0 | 53 |
| OPEN LABEL MAXIMAL USE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TAPINAROF CREAM, 1% IN PEDIATRIC SUBJECTS WITH EXTENSIVE ATOPIC DERMATITIS | $67,052 | 0 | 176 |
| A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PLAQUE PSORIASIS OCCURRING IN THE HEAD AND NECK REGION | $57,765 | 0 | 241 |
| 60061781-02 | $15,356 | 0 | 1 |
| A PHASE 4, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF VTAMA (TAPINAROF) CREAM, 1% IN THE TREATMENT OF PLAQUE PSORIASIS IN INTERTRIGINOUS AREAS | $14,300 | 0 | 5 |
| DMVT-505-3004-0149 | $8,948 | 0 | 1 |
| DMVT-505-3004-0299 | $5,696 | 0 | 1 |
| DMVT-505-3004-0277 | $5,306 | 0 | 1 |
| DMVT-505-3004-0138 | $5,097 | 0 | 1 |
| DMVT-505-3004-0126 | $5,000 | 0 | 1 |
| DMVT-505-3004-0324 | $4,861 | 0 | 1 |
| DMVT-505-3004-0311 | $4,690 | 0 | 1 |
| DMVT-505-3004-0116 | $4,588 | 0 | 1 |
| DMVT-505-3004-0327 | $4,184 | 0 | 1 |
| DMVT-505-3004-0113 | $3,362 | 0 | 1 |
| DMVT-505-3004-0313 | $3,346 | 0 | 1 |
| DMVT-505-3004-0122 | $3,191 | 0 | 1 |
| DMVT-505-3004-0301 | $3,016 | 0 | 1 |
| DMVT-505-3004-0314 | $2,996 | 0 | 1 |
| DMVT-505-3004-0134 | $2,908 | 0 | 1 |
| DMVT-505-3004-0310 | $2,879 | 0 | 1 |
| DMVT-505-3004-0114 | $2,812 | 0 | 1 |
| DMVT-505-3004-0283 | $2,760 | 0 | 1 |
| DMVT-505-3004-0291 | $2,700 | 0 | 1 |
| DMVT-505-3004-0303 | $2,609 | 0 | 1 |
| DMVT-505-3004-0137 | $2,482 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 549
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Melissa Serravallo, M.d, M.D | Dermatology | Yardley, PA | $11.72 | $0 |
| Andrew Ellenwood, Fnp-C, FNP-C | Nurse Practitioner | Fishers, IN | $11.69 | $0 |
| Richard Sturm, M.d, M.D | Specialist | Atlanta, GA | $11.67 | $0 |
About Dermavant Sciences, Inc.
Dermavant Sciences, Inc. has made $22.8M in payments to 13,703 healthcare providers, recorded across 151,076 transactions in the CMS Open Payments database. In 2024, the company paid $6.8M. The top product by payment volume is VTAMA ($21.3M).
Payments were distributed across 131 medical specialties. The top specialty by payment amount is Dermatology ($8.2M to 5,003 doctors).
Payment categories include: Food & Beverage ($3.0M), Consulting ($3.6M), Research ($8.9M), Travel & Lodging ($832,583).
Dermavant Sciences, Inc. is associated with 2 products in the CMS Open Payments database.